Researchers investigate the multi-omic landscape of steatosis-to-NASH progression in mice

The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be > 25% and will continue to rise. NAFLD comprises a spectrum of liver disorders ranging from simple steatosis (NAFL) to nonalcoholic steatohepatitis (NASH). While NAFL is generally considered to be a benign condition, NASH is prone to develop into severe end-stage liver diseases. However, the molecular mechanisms of steatosis-to-NASH progression remain poorly understood.